Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Revance Therapeutics, Inc. | rvnc1231201410k.htm |
| EX-31.1 - EXHIBIT 31.1 - Revance Therapeutics, Inc. | rvnc1231201410kex311.htm |
| EX-32.1 - EXHIBIT 32.1 - Revance Therapeutics, Inc. | rvnc1231201410kex321.htm |
| EX-31.2 - EXHIBIT 31.2 - Revance Therapeutics, Inc. | rvnc1231201410kex312.htm |
| EX-10.40 - EXHIBIT 10.40 - Revance Therapeutics, Inc. | rvnc1231201410kex1040.htm |
| EX-10.42 - EXHIBIT 10.42 - Revance Therapeutics, Inc. | rvnc1231201410kex1042.htm |
| EX-10.25 - EXHIBIT 10.25 - Revance Therapeutics, Inc. | rvnc1231201410kex1025.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Revance Therapeutics, Inc. | Financial_Report.xls |
| EX-32.2 - EXHIBIT 32.2 - Revance Therapeutics, Inc. | rvnc1231201410kex322.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S‑8 (Nos. 333- 193963 and 333-198499) of Revance Therapeutics Inc. of our report dated March 4, 2015 relating to the financial statements, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
San Jose, California
San Jose, California
March 4, 2015